ArticleClinical and translational radiation oncology2019

Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials.

Linda Spiegelberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.